.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,067,114

« Back to Dashboard

Details for Patent: 7,067,114

Title:Delivery of antihistamines through an inhalation route
Abstract: The present invention relates to the delivery of antihistamines through an inhalation route. Specifically, it relates to aerosols containing antihistamines that are used in inhalation therapy. In a method aspect of the present invention, an antihistamine is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antihistamine, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antihistamine drug degradation products. In a kit aspect of the present invention, a kit for delivering an antihistamine through an inhalation route is provided which comprises: a) a thin layer of an antihistamine drug and b) a device for dispensing said thin layer as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:Jan 29, 2004
Application Number:10/768,293
Claims:1. A condensation aerosol for delivery of a drug selected from the group consisting of azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine and promethazine, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol is formed at a rate greater than 10.sup.9 particles per second.

3. The condensation aerosol according to claim 2, wherein the condensation aerosol is formed at a rate greater than 10.sup.10 particles per second.

4. A method of producing a drug selected from the group consisting of azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine and promethazine in an aerosol form comprising: a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

5. The method according to claim 4, wherein the condensation aerosol is formed at a rate greater than 10.sup.9 particles per second.

6. The method according to claim 5, wherein the condensation aerosol is formed at a rate greater than 10.sup.10 particles per second.

7. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

8. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

9. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.

10. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

11. The condensation aerosol according to claim 10, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

12. The condensation aerosol according to claim 1, wherein the solid support is a metal foil.

13. The condensation aerosol according to claim 1, wherein the drug is azatadine.

14. The condensation aerosol according to claim 1, wherein the drug is brompheniramine.

15. The condensation aerosol according to claim 1, wherein the drug is carbinoxamine.

16. The condensation aerosol according to claim 1, wherein the drug is chlorpheniramine.

17. The condensation aerosol according to claim 1, wherein the drug is clemastine.

18. The condensation aerosol according to claim 1, wherein the drug is cyproheptadine.

19. The condensation aerosol according to claim 1, wherein the drug is loratadine.

20. The condensation aerosol according to claim 1, wherein the drug is pyrilamine.

21. The condensation aerosol according to claim 1, wherein the drug is hydroxyzine.

22. The condensation aerosol according to claim 1, wherein the drug is promethazine.

23. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

24. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

25. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.

26. The method according to claim 4, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

27. The method according to claim 26, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

28. The method according to claim 4, wherein the solid support is a metal foil.

29. The method according to claim 4, wherein the drug is azatadine.

30. The method according to claim 4, wherein the drug is brompheniramine.

31. The method according to claim 4, wherein the drug is carbinoxamine.

32. The method according to claim 4, wherein the drug is chlorpheniramine.

33. The method according to claim 4, wherein the drug is clemastine.

34. The method according to claim 4, wherein the drug is cyproheptadine.

35. The method according to claim 4, wherein the drug is loratadine.

36. The method according to claim 4, wherein the drug is pyrilamine.

37. The method according to claim 4, wherein the drug is hydroxyzine.

38. The method according to claim 4, wherein the drug is promethazine.

39. A condensation aerosol for delivery of azatadine, wherein the condensation aerosol is formed by heating a thin layer containing azatadine, on a solid support, to produce a vapor of azatadine, and condensing the vapor to form a condensation aerosol characterized by less than 5% azatadine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

40. A condensation aerosol for delivery of brompheniramine, wherein the condensation aerosol is formed by heating a thin layer containing brompheniramine, on a solid support, to produce a vapor of brompheniramine, and condensing the vapor to form a condensation aerosol characterized by less than 5% brompheniramine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

41. A condensation aerosol for delivery of carbinoxamine, wherein the condensation aerosol is formed by heating a thin layer containing carbinoxamine, on a solid support, to produce a vapor of carbinoxamine, and condensing the vapor to form a condensation aerosol characterized by less than 5% carbinoxamine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

42. A condensation aerosol for delivery of chlorpheniramine, wherein the condensation aerosol is formed by heating a thin layer containing chlorpheniramine, on a solid support, to produce a vapor of chlorpheniramine, and condensing the vapor to form a condensation aerosol characterized by less than 5% chlorpheniramine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

43. A condensation aerosol for delivery of clemastine, wherein the condensation aerosol is formed by heating a thin layer containing clemastine, on a solid support, to produce a vapor of clemastine, and condensing the vapor to form a condensation aerosol characterized by less than 5% clemastine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

44. A condensation aerosol for delivery of cyproheptadine, wherein the condensation aerosol is formed by heating a thin layer containing cyproheptadine, on a solid support, to produce a vapor of cyproheptadine, and condensing the vapor to form a condensation aerosol characterized by less than 5% cyproheptadine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

45. A condensation aerosol for delivery of loratadine, wherein the condensation aerosol is formed by heating a thin layer containing loratadine, on a solid support, to produce a vapor of loratadine, and condensing the vapor to form a condensation aerosol characterized by less than 5% loratadine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

46. A condensation aerosol for delivery of pyrilamine, wherein the condensation aerosol is formed by heating a thin layer containing pyrilamine, on a solid support, to produce a vapor of pyrilamine, and condensing the vapor to form a condensation aerosol characterized by less than 5% pyrilamine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

47. A condensation aerosol for delivery of hydroxyzine, wherein the condensation aerosol is formed by heating a thin layer containing hydroxyzine, on a solid support, to produce a vapor of hydroxyzine, and condensing the vapor to form a condensation aerosol characterized by less than 5% hydroxyzine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

48. A condensation aerosol for delivery of promethazine, wherein the condensation aerosol is formed by heating a thin layer containing promethazine, on a solid support, to produce a vapor of promethazine, and condensing the vapor to form a condensation aerosol characterized by less than 5% promethazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

49. A method of producing azatadine in an aerosol form comprising: a. heating a thin layer containing azatadine, on a solid support, to produce a vapor of azatadine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% azatadine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

50. A method of producing brompheniramine in an aerosol form comprising: a. heating a thin layer containing brompheniramine, on a solid support, to produce a vapor of brompheniramine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% brompheniramine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

51. A method of producing carbinoxamine in an aerosol form comprising: a. heating a thin layer containing carbinoxamine, on a solid support, to produce a vapor of carbinoxamine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% carbinoxamine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

52. A method of producing chlorpheniramine in an aerosol form comprising: a. heating a thin layer containing chlorpheniramine, on a solid support, to produce a vapor of chlorpheniramine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% chlorpheniramine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

53. A method of producing clemastine in an aerosol form comprising: a. heating a thin layer containing clemastine, on a solid support, to produce a vapor of clemastine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% clemastine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

54. A method of producing cyproheptadine in an aerosol form comprising: a. heating a thin layer containing cyproheptadine, on a solid support, to produce a vapor of cyproheptadine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% cyproheptadine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

55. A method of producing loratadine in an aerosol form comprising: a. heating a thin layer containing loratadine, on a solid support, to produce a vapor of loratadine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% loratadine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

56. A method of producing pyrilamine in an aerosol form comprising: a. heating a thin layer containing pyrilamine, on a solid support, to produce a vapor of pyrilamine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% pyrilamine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

57. A method of producing hydroxyzine in an aerosol form comprising: a. heating a thin layer containing hydroxyzine, on a solid support, to produce a vapor of hydroxyzine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% hydroxyzine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

58. A method of producing promethazine in an aerosol form comprising: a. heating a thin layer containing promethazine, on a solid support, to produce a vapor of promethazine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% promethazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc